Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (AfterDmab)
2016-000852-91Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of zoledronic acid in postmenopausal osteoporosis (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Lumbar spine bone mineral density at 24 months, Hip bone mineral density at 24 months and 1 more. Started Mar 2016; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2016-000852-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000852-91.